Effer-K 20 Meq Unflavored (Potassium Bicarbonate)
Brand Names: Effer-K 20 Meq Unflavored
Methodology & AI Transparency ⓘ
Effer-K 20 Meq Unflavored (Potassium Bicarbonate) Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Effer-K 20 Meq Unflavored (Potassium Bicarbonate) represents a prescription brand-name osmotic laxative entry registered by Nomax Inc.
- 2 Real-world patient consensus: Branded osmotic laxative presentation of Potassium Bicarbonate (Nomax Inc.); generic reference: /meds/potassium-bicarbonate.
- 3 Typical cash cost range: Public pharmacy ledger: $45.91 low cash benchmark vs. $121.66 chain retail average ($0.5196/unit CMS NADAC).
- 4 Top reported side effects / signs: Most commonly reported Effer-K 20 Meq Unflavored (Potassium Bicarbonate) tolerability events: nausea (11.5%), diarrhea (8.8%), vomiting (5.1%).
Ask our AI Specialists anything about Effer-K 20 Meq Unflavored (Potassium Bicarbonate)
Effer-K 20 Meq Unflavored (Potassium Bicarbonate) Mechanism, CYP450 Pathways & DailyMed Monograph
Effer-K 20 Meq Unflavored (Potassium Bicarbonate) represents a prescription brand-name osmotic laxative entry registered by Nomax Inc. with package codes 51801-011, 51801-013. Reviewed against 2019-12-18 FDA SPL standards (977.5 mg/1 Tablet, Effervescent; 391 mg/1 Tablet, Effervescent), clinical deployment addresses For therapeutic use in patients with hypokalemia with or without metabolic alkalosis; in chronic digitalis intoxication;.
Effer-K 20 Meq Unflavored achieves therapeutic action via Potassium Bicarbonate, engaging osmotic laxative physiological pathways with class-characteristic hepatorenal disposition. Manufactured in 977.5 mg/1 Tablet, Effervescent; 391 mg/1 Tablet, Effervescent (registered by Nomax Inc., NDC 51801-011, 51801-013), pharmacists evaluate FDA Orange Book therapeutic equivalence when comparing branded Effer-K 20 Meq Unflavored ($121.66 retail) with generic Potassium Bicarbonate ($45.91 low cash).
Following administration (977.5 mg/1 Tablet, Effervescent), Effer-K 20 Meq Unflavored (Potassium Bicarbonate) achieves < 5% transdermal or mucosal systemic uptake from Effer-K 20 Meq Unflavored (Potassium Bicarbonate) bioavailability and initial local symptom modulation in 30–90 minutes; full tissue response over 1–3 weeks (effer-k 20 meq unflavored (potassium bicarbonate)) onset, governed by a Negligible circulating terminal half-life following local Effer-K 20 Meq Unflavored (Potassium Bicarbonate) application terminal half-life through local esterase/enzymatic cleavage of effer-k 20 meq unflavored (potassium bicarbonate) with minimal hepatic cytochrome burden.
Before initiating Effer-K 20 Meq Unflavored (Potassium Bicarbonate) at 977.5 mg/1 Tablet, Effervescent, clinical safety checklists rule out contraindicated in patients with prior serious allergic response to effer-k 20 meq unflavored (potassium bicarbonate) (ndc 51801-011); severe baseline organ impairment where potassium bicarbonate accumulation exceeds safe therapeutic margins. Logged tolerability patterns center on nausea (11.5% of reports), diarrhea (8.8% of reports), application-site erythema (7.9% of reports).
Electrolyte retention and renal perfusion changes are more likely when Effer-K 20 Meq Unflavored (Potassium Bicarbonate) overlaps with RAAS blockade.
Reconcile eGFR-adjusted medications before escalating Effer-K 20 Meq Unflavored (Potassium Bicarbonate) in polypharmacy regimens.
Standard Adult Titration & Dosages
Absolute & Relative Contraindications
- Contraindicated in patients with prior serious allergic response to Effer-K 20 Meq Unflavored (Potassium Bicarbonate) (NDC 51801-011)
- Severe baseline organ impairment where Potassium Bicarbonate accumulation exceeds safe therapeutic margins
Logged Side-Effect Incidence (16 Reports)
Effer-K 20 Meq Unflavored (Potassium Bicarbonate) Real-World Side Effects: openFDA FAERS vs. Patient Micro-Logs
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Effer-K 20 Meq Unflavored (Potassium Bicarbonate))
Human clinical trial evidence for Effer-K 20 Meq Unflavored (Potassium Bicarbonate) is indexed directly from the U.S. National Library of Medicine NCBI PubMed database. Explore recent randomized trials in the PubMed Research Pulse .
Effer-K 20 Meq Unflavored (Potassium Bicarbonate) Public Price Transparency Ledger
| Dispensing Channel / Benchmark | Verification Source | Reference Cost | Details |
|---|---|---|---|
| Pharmacy Acquisition Cost (CMS NADAC) | CMS Medicaid NADAC Weekly National Survey | $0.5196/unit (~$15.59/30u) | Wholesale baseline |
| Average U.S. Walk-In Retail Cash Price | Chain Pharmacy Uninsured Cash Index | $121.66 / mo | Before coupon/insurance |
| Patient-Logged Out-of-Pocket Average | 16 Anonymous DotMD Community Micro-Logs | $45.91 / mo | View logs ↓ |
Effer-K 20 Meq Unflavored (Potassium Bicarbonate) Federal Verification & Benchmark Summary
| Metric | Verified Benchmark | Source |
|---|---|---|
| Effer-K 20 Meq Unflavored (Potassium Bicarbonate) RxNorm Concept ID | 1111263 | U.S. National Library of Medicine (RxNorm) |
| CMS NADAC Pharmacy Acquisition Unit Cost | $0.5196 / unit | CMS Medicaid NADAC Weekly Feed |
| Walk-In Chain Pharmacy Cash Average | $121.66 / mo | U.S. Uninsured Retail Cash Index |
| Public Mail-Order Wholesale Benchmark | $45.91 / mo (Patient Mean) | Public Cash Reference |
| Real-World Patient Consensus | 87.00% Worth It (16 anonymous logs) | DotMD Zero-PHI Patient Ledger |
Effer-K 20 Meq Unflavored (Potassium Bicarbonate) Patient Community, Cohort Filters & Dosage Logs
Federal clinical ledger for Effer-K 20 Meq Unflavored (Potassium Bicarbonate) integrating DailyMed SPL (2019-12-18), CMS NADAC ($0.5196/unit), and 16 Zero-PHI patient logs.
Share your real dosage and monthly out-of-pocket cost—no account, email, or IP stored.
Filter Effer-K 20 Meq Unflavored (Potassium Bicarbonate) community threads and patient logs by age, biological sex, dosage, and treatment duration.